Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005763 | 0.85 | SYK (0.63) | SYK | |
| SCHEMBL17005748 | 0.84 | SYK (0.61) | SYK | |
| SCHEMBL18351855 | 0.81 | SYK (0.63) | SYKALDH1A1HPGD | |
| SCHEMBL17005751 | 0.79 | SYK (0.64) | SYK | |
| SCHEMBL17005759 | 0.78 | SYK (0.55) | SYKAXL | |
| SCHEMBL18351942 | 0.78 | SYK (1.00) | SYK | |
| SCHEMBL18351941 | 0.78 | SYK (1.00) | SYK | |
| SCHEMBL17620616 | 0.76 | KDR (0.70) | SYKALDH1A1HPGDSMN1; SMN2KDR | |
| SCHEMBL17005771 | 0.74 | OPRM1 (0.62) | SYKSMN1; SMN2 | |
| SCHEMBL9955095 | 0.73 | KDR (0.84) | ALDH1A1HPGDSMN1; SMN2KDRCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533989-B2 | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | Ziarco Pharma Ltd. (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | PFIZER LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | SYK, BTK, LCK | SYK 1/4885ALDH1A1 2268/4885HPGD 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.